Supercomputer simulation reveals possible solutions to antibiotic resistance

Antibiotic resistance is here, and researchers have been scrambling to find a possible solution to fight back. In simulations conducted on a supercomputer at the Department of Energy's Oak Ridge National Laboratory (ORNL) in Tennessee, researchers have uncovered a new class of drug candidates that might be the leading weapon in fighting antibiotic resistance.

Researchers from the University of Oklahoma with ORNL, University of Tennessee and Saint Louis University have combined a number of lab experiments with supercomputer modeling to seek the molecules capable of boosting antibiotics effects on dangerous bacteria.

"The supercomputing power of Titan allowed us to perform large-scale simulations of the drug targets and to screen many potential compounds quickly," said Helen Zgurskaya, head of the University of Oklahoma's Antibiotic Discovery and Resistance Group, who led the study. "The information we received was combined with our experiments to select molecules that were found to work well, and this should drastically reduce the time needed to move from the experimental phase to clinical trials."

The simulations revealed four new chemicals capable of interfering with the efflux pumps within a bacterium. The efflux pumps, being the direct cause of antibiotic resistance within the AcrA protein, are able to connect two proteins in a tunnel through the bacterial cell envelope. The AcrA protein was signaled out by researchers because if they are able to disrupt the connection of proteins, they would stop the efflux pump.

"As a first in this field, we proposed the approach of essentially 'screwing up' the efflux pump's protein assembly, and this led to the discovery of molecules with a new type of antibacterial activity," said co-author Jeremy Smith, director of the UT-ORNL Center for Molecular Biophysics. "In contrast to previous approaches, our new mechanism uses mechanics to revive existing antibiotics' ability to fight infection."

 

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.